Paula Cobb
Director/Board Member at PROTHENA CORPORATION PLC
Net worth: - $ as of 30/04/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Gene Kinney | M | 55 | 12 years | |
Caroline Dorsa | F | 64 | 14 years | |
Tran Nguyen | M | 50 | 11 years | |
Stephen Sherwin | M | 75 | 14 years | |
Oleg Nodelman | M | 47 | 5 years | |
Nicole Murphy | F | - | 9 years | |
Carole Faig | F | 62 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 3 years |
Michael Hencke | M | - | 12 years | |
Helen Elizabeth Hanby | F | 58 |
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | - |
Luk Vandenberghe | M | 47 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 years |
Michael J. Malecek | M | 58 | 5 years | |
Randy Fawcett | M | - | - | |
Wagner M. Zago | M | 51 | 12 years | |
Caroline Stout | F | 33 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 3 years |
Brandon Smith | M | 50 | 4 years | |
Richard Collier | M | 70 | 12 years | |
Rick Modi | M | 55 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 years |
Lars Ekman | M | 74 | 12 years | |
Susan Alexander | F | 67 | 21 years | |
Charles Sigal | M | 72 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 years |
Eric Rowinsky | M | 67 | 14 years | |
Sean Nolan | M | 56 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 years |
Dennis Selkoe | M | 80 | 11 years | |
Karl Härfstrand | M | 66 | 9 years | |
Daniel Welch | M | 66 | - | |
Ed Mathers Mathers | M | 64 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 years |
Shane Cooke | M | 61 | 12 years | |
Dave Grayzel | M | 56 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 years |
Yvonne M. Tchrakian | F | - | 10 years | |
Aaron Tward | M | - |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 years |
Michael Bachner | M | - | 2 years | |
Robert May | M | 56 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 years |
Rob Aboud | M | 59 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 years |
Petra Kaufmann | M | 58 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 3 years |
Laura Richman | M | 60 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 years |
Helen Kim | F | 61 | 2 years | |
Karin Walker | F | 60 | 11 years | |
Charles Albright | M | 66 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 3 years |
Carol Karp | F | 71 | 8 years | |
Botond Roska | M | 54 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 years |
Lori Elizabeth Mochan | F | 47 |
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | - |
Diana Brainard | M | 53 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 2 years |
Hideki Garren | M | 60 | 3 years | |
Michael Dambach | M | 57 | 17 years | |
William Dunn | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
George Scangos | M | 76 | 7 years | |
Trevor Anthony Mill | M | 53 | 9 years | |
William Rastetter | M | 76 | 19 years | |
William Young | M | 79 | 11 years | |
James Mullen | M | 65 | 21 years | |
Stelios Papadopoulos | M | 75 | 15 years | |
Joseph Mara | M | 49 | - | |
Neil Exter | M | 65 | 5 years | |
Nancy L. Leaming | F | 76 | 14 years | |
Gilmore O’Neill | M | 59 | 15 years | |
Jennifer Zibuda | F | - | 3 years | |
Chris Hollowood | M | 50 | 6 years | |
Douglas Kerr | M | 57 | 2 years | |
James McArthur | M | 62 | 3 years | |
Richard Mulligan | M | 69 | 14 years | |
Bryan Yoon | M | 46 | 2 years | |
John Lee | M | 56 | 5 years | |
Senthil Sundaram | M | 46 | 2 years | |
Lynne Sullivan | F | 58 | 10 years | |
Sanjiv Patel | M | 50 | 2 years | |
Samantha Truex | F | - | 8 years | |
Carlos Costa | M | 51 | 7 years | |
Robert A. Hamm | M | 72 | 7 years | |
Ronald Vigliotta | M | 51 | 5 years | |
Phillip Sharp | M | 79 | 31 years | |
Craig Eric Schneier | M | 76 | 8 years | |
Michael Gilman | M | 69 | 8 years | |
Scott Whitcup | M | 64 | 2 years | |
Gina Consylman | F | 52 | 3 years | |
Christine Poon | F | 71 | 2 years | |
David Mott | M | 58 | 4 years | |
Christopher Henney | M | 83 | 9 years | |
Eric S. Hoffman | M | 54 | 5 years | |
Brian Posner | M | 62 | 14 years | |
Alexander Denner | M | 54 | 14 years | |
Sylvie Grégoire | M | 63 | 8 years | |
Gregory Covino | M | 59 | 6 years | |
David Lubner | M | 60 | 2 years | |
Adriana Bokel Herde | F | - | 6 years | |
Dell Faulkingham | M | 51 | 9 years | |
Andrea DiFabio | F | 55 | 11 years | |
Mark Wiggins | M | 68 | 11 years | |
Richard Ransohoff | M | - | 3 years | |
Carmen Bozic | M | 61 | 6 years | |
Ben Harshbarger | M | 55 | 5 years | |
Donald R. Johns | M | - | 2 years | |
Olivier Danos | M | 66 | 3 years | |
Kiran Reddy | M | 47 | 2 years | |
Jeffrey D. Bornstein | M | - | 3 years | |
Keith Regnante | M | 54 | 14 years | |
Timothy Harris | M | 74 | 1 years | |
Katherine J. Turner | M | 70 | 4 years | |
John McDonald | M | 63 | 7 years | |
Adam Koppel | M | 54 | 2 years | |
Bonne Adams | F | 47 | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 68 | 68.00% |
Ireland | 23 | 23.00% |
United Kingdom | 10 | 10.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Paula Cobb
- Personal Network